TGFB1 and pancreatic neoplasm: Given the adverse outcomes observed following direct targeting of TGFβ1 in pancreatic cancer patients [34], we explored whether other cytokines downstream of TGFβ1, which may be more favorable therapeutic targets, were implicated in the EMT-associated changes in morphology that we observed.